A systematic review update of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists

Health Technology Assessment

Volumn 6, Issue 25, 2002, Pages

  Robinson, M ^b   Ginnelly, L ^a   Sculpher, M ^a   Jones, L ^a   Riemsma, R ^a   Palmer, S ^a   Philips, Z ^a   Glanville, J ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANTIANGINA PECTORIS AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; LAMIFIBAN; LANOTEPLASE; LOW MOLECULAR WEIGHT HEPARIN; MORPHINE; NITRATE; PLACEBO; RETEPLASE; STREPTOKINASE; TENECTEPLASE; TICLOPIDINE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CAUSE OF DEATH; CLINICAL TRIAL; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DEATH; DOSE RESPONSE; DRUG BINDING; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG USE; FIBRINOLYTIC THERAPY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; OUTCOMES RESEARCH; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; STROKE; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 0036916166     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta6250     Document Type: Review

References (123)

1. Bosch X, Marrugat J. Platelet glycoprotein IIb/IIIa blockers for percutaneous transluminal coronary angioplasty and unstable angina (Cochrane Review). In: The Cochrane Library. Issue 4. Oxford: Update Software; 2001.
2. Boersma E, Harrington R, Moliterno D, White H, Theroux P, Van De Werf E, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. A meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-98.
3. McDonagh MS, Bachmann LM, Golder S, Kleijnen J, Ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina. Health Technol Assess 2000;4(30):1-95.
4. Fischer A, Frankish R, Taylor RT. Clinical and Cost Effectiveness of Glycoprotein IIb/IIIa Inhibitors in Association with Percutaneous Coronary Intervention (PCI). London: National Institute for Clinical Excellence, 2000.
5. Department of Health. National Service Framework for Coronary Heart Disease. London: Department of Health; 2000.
6. Erens B, Primatesta P, editors. Cardiovascular Disease '98. London: Stationery Office; 1999.
7. Lawlor D, Ebrahim S, Davey Smith G. Sex matters: Secular and geographical trends in sex differences in coronary heart disease mortality. BMJ 2001;323:541-5.
8. Rosengren A, Wilhelmsen L, Hagman M, Wedel H. Natural history of myocardial infarction and angina pectoris in a general population sample of middle-aged men: A 16-year follow-up of the Primary Prevention Study, Goteborg, Sweden. J Intern Med 1998;244:495-505.
9. Rizik DG, Healey S, Margulis A, Vandam D, Bakalyar D, Timmis G, et al. A new clinical classification for hospital prognosis of unstable angina pectoris. Am J Cardiol 1995;75:993-7.
10. Muller JE, Turi ZG, Pearle DL, Schneider JF, Serfas DH, Morrison J, et al. Nifedipine and conventional therapy for unstable angina pectoris: A randomised double-blind comparison. Circulation 1984;69:728-39.
11. Nyman I, Areskog M, Areskog NH, Swahn E, Wallentin L. Very early risk stratification by electrocardiogram at rest in men with suspected unstable coronary heart disease. The RISC Study Group. J Intern Med 1993;234:293-301.
12. Wilcox I, Freedman SB, McCredie RJ, Carter GS, Kelly DT, Harris P. Risk of adverse outcome in patients admitted to the coronary care unit with suspected unstable angina pectoris. Am J Cardiol 1989;64:845-8.
13. Cairns JA, Singer J, Gent M, Holder DA, Rogers D, Sackett DL, et al. One year mortality outcomes of all coronary and intensive care unit patients with acute myocardial infarction, unstable angina or other chest pain in Hamilton, Ontario, a city of 375,000 people. Can J Cardiol 1989;5:239-46.
14. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992;327:141-5.
15. Theroux P, Taeymans Y, Morissette D, Bosch X, Pelletier GB, Waters DD. A randomised study comparing propanolol and diltiazem in the treatment of unstable angina. J Am Coll Cardiol 1985;5:717-22.
16. Theroux P, Waters D, Qiu S, McCans J, De Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993;88:2045-8.
17. White LD, Lee TH, Cook EF, Weisberg MC, Rouan GW, Brand DA, et al. Comparison of the natural history of new onset and exacerbated chronic ischemic heart disease. J Am Coll Cardiol 1990;16:304-10.
18. Karlson BW, Herlitz J, Pettersson P, Hallgren P, Strombom U, Hjalmarson A. One-year prognosis in patients hospitalized with a history of unstable angina pectoris. Clin Cardiol 1993;16:397-402.
19. Pocock SJ, Henderson RA, Rickards AF, Hampton JR, King SB 3rd, Hamm CW, et al. Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery. Lancet 1995;346:1184-9.
20. Sculpher MJ, Petticrew M, Kelland JL, Elliott RA, Holdright DR, Buxton MJ. Resource allocation for chronic stable angina: A systematic review of effectiveness, costs and cost-effectiveness of alternative interventions. Health Technol Assess 1998;2(10):1-175.
21. Meads C, Cummins C, Jolly K, Stevens A, Burls A, Hyde C. Coronary artery stents in the treatment of ischaemic heart disease: A rapid and systematic review. Health Technol Assess 2000;4(23):1-143.
22. Topol EJ. Acute myocardial infarction: Thrombolysis. Heart 2000;83:122-6.
23. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardio (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;i:397-402.
24. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;ii:349-60.
25. GUSTO-Investigators. An international randomised trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
26. White HD. Future of reperfusion therapy for acute myocardial infarction. Lancet 1999;354:695-7.
27. Gandhi MM, Lampe FC, Wood DA. Incidence, clinical characteristics, and short-term prognosis of angina pectoris. Br Heart J 1995;73:193-8.
28. Purcell H. The epidemiology of unstable angina. Br J Cardiol 1998;5 Suppl 2:S3-S4.
29. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary 42. London: British Medical Association; 2001.
30. Infarction Audit Group. Trends in the provision of thrombolytic treatment between 1993 and 1997. Infarction Audit Group. Heart 1999;82:438-42.
31. British Cardiovascular Intervention Society. BCIS Audit Returns of Interventional Procedures 2000. London: British Cardiovascular Intervention Society; 2000.
32. Charo I, Bekeart L, Phillips D. Platelet glycoprotein IIb-IIIa-like proteins mediate endothelial cell attachment to adhesive proteins and the extracellular matrix. J Biol Chem 1987;262:9935-8.
33. Chesebro JH, Badimon JJ. Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease. N Engl J Med 1998;338:1539-41.
34. Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 1998;77:670-7.
35. Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab following thrombolytic therapy: Results of the TAMI 8 pilot study. J Am Coll Cardiol 1993;22:381-9.
36. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial. Lancet 2001;357:1915-24.
37. Schulman SP, Goldschmidt Clermont PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, et al. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation 1996;94:2083-9.
38. Harrington RA. Design and methodology of the PURSUIT trial: Evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol 1997;80(4A):34B-8B.
39. The PURSUIT Trial Investigators. PURSUIT (Platelet IIb/IIIa in unstable angina: Receptor suppression using Integrelin™ therapy). Clin Cardiol 1997;20(11):967.
40. Simoons ML. New findings from the PURSUIT study. Eur Heart J Suppl 1999;1(N):N30-4.
41. Mahaffey KW, Harrington RA, Simoons ML, Granger CB, Graffagnino C, Alberts MJ, et al. Stroke in patients with acute coronary syndromes: Incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. Circulation 1999;99:2371-7.
42. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339:436-43.
43. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
44. Bazzino O, Barrero C, Garre L, Sosa A, Aylward P, Slany J, et al. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
45. Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 1999;354:1757-62.
46. Theroux P, Alexander J, Pharand C, Barr E, Snapinn S, Ghannam AF, et al. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation 2000;102:2466-72.
47. Hasdai D, Holmes DR, Criger DA, Topol EJ, Califf RM, Harrington RA. Age and outcome after acute coronary syndromes without persistent ST-segment elevation. Am Heart J 2000;139:858-66.
48. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: Results from an international trial of 9461 patients. Circulation 2000;101:2557-67.
49. Chesebro J, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen JE, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I. Circulation 1987;76:142-54.
50. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
51. Clarke M, Halsey J. DICE 2: A further investigation of the effects of chance in life, death and subgroup analyses. Int J Clin Pract 2001;55 Suppl 4:240-2.
52. Knight C. National Institute of Clinical Excellence Guidance: Too NICE to GP IIb/IIIa antagonists? Heart 2001;85:481-3.
53. Manoharan G, Adgey AA. Glycoprotein IIb/IIIa inhibitors and acute coronary syndromes: Summary report of the full submission to NICE, and beyond. Heart 2001;86:259-61.
54. Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 1999;100:2045-8.
55. Mahaffey KW, Harrington RA, Simoons ML, Granger CB, Graffagnino C, Alberts MJ, et al. Stroke in patients with acute coronary syndromes: Incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. Circulation 1999;99:2371-7.
56. Verstraete M, Adam PC, Pemberton J, Evemy KL. Exit of platelet glycoprotein-IIb/IIIa-receptor inhibitors? Lancet 2001;357:1535-6.
57. Braunwald E. Non-ST elevation ACS: The moving target of anti-thrombotic therapies. In: Program and Abstracts from the American Heart Association Scientific Sessions. Plenary Session II: Evidence-based Management of Acute Coronary Syndromes 2001; 2001; 2001 Nov 11-4; Anaheim (CA), USA.
58. Palmer S, Sculpher M, Philips Z, Robinson M, Ginnelly L, Bakhai A, et al. A cost-effectiveness model comparing alternative management strategies for the use glycoprotein IIb/IIIa antagonists in acute coronary syndrome. Draft report for the National Institute for Clinical Excellence. York: Centre for Health Economics; April 2001.
59. O'Neil WW, Serruys P, Knudtson M, Van Es GA, Timmis GC, Van Der Zwaan C, et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of oral Xemilofiban in controlling thrombotic events. N Engl J Med 2000;342:1316-24.
60. Lam W, Gill JB, Trask RV, Mallavarapu CT, Rocha Singh KJ, Mikell FL, et al. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro Versus Integrilin Cost Evaluation (PRICE) trial. Am Heart J 2001;141:402-9.
61. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903.
62. Cannon CP, Weintraub WS, Demopoulos LA, Robertson DH, Gormley GJ, Braunwald E. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: Rationale and study design of the international TACTICS-TIMI 18 trial. Am J Cardiol 1998;82:731-6.
63. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-94.
64. O'Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: The ESPRIT trial: A randomized controlled trial. JAMA 2001;285:2468-73.
65. Stone GW, Grines CL, Cox DA, et al. A prospective, randomized trial comparing primary balloon angioplasty with or without abciximab to primary stenting with or without abciximab in acute myocardial infarction: Primary endpoint analysis from the CADILLAC Trial. Circulation 2000;102:664.
66. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997;349:1422-8.
67. Hanrath P, Vom Dahl J, Paulus O, Heyndrickx G, Sosa JA, Muller D, et al. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
68. Gibson CM, Goel M, Cohen DJ, Piana RN, Deckelbaum LI, Harris KE, et al. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. J Am Coll Cardiol 1998;32:28-34.
69. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study. Lancet 1997;349:1429-35.
70. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956-61.
71. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. The EPIC Investigators. Lancet 1994;343:881-6.
72. Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997;278:479-84.
73. Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab. One-year outcome in the EPILOG trial. Circulation 1999;99:1951-8.
74. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689-96.
75. Brener SJ, Barr LA, Burchenal JEB, Katz S, George BS, Jones AA, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998;98:734-41.
76. Topol EJ, Lincoff AM, Califf RM, Tcheng JE, Cohen EA, Kleiman NS, et al. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
77. Ellis SG, Effron MB, Gold HK, Leon MB, Popma JJ, Serruys P. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation 1999;100:799-806.
78. Galassi AR, Russo G, Nicosia A, Tamburino C, Foti R, Rodi G, et al. Usefulness of platelet glycoprotein IIb/IIIa inhibitors in coronary stenting for reconstruction of complex lesions: Procedural and 30 day outcome. Cardiologia 1999;44:639-45.
79. Chen YH, Chen JW, Wu TC, Ding PA, Wang SP, Chang MS. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty. Chin Med J (Taipei) 2000;63:8-15.
80. Neumann FJ, Kastrati A, Schmitt C, Blasini R, Hadamitzky M, Mehilli J, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000;35:915-21.
81. Harrington RA, Kleiman NS, Kottke Marchant K, Lincott AM, Tcheng JE, Sigmon KN, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76:1222-7.
82. Manoharan G, Maynard SJ, Adgey AAJ. The therapeutic use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Expert Opin Investig Drugs 1999;8:555-6.
83. Van De Werf F, Armstrong PW, Granger C, Wallentin L. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-13.
84. Antman EM, Gibson CM, De Lemos JA, Giugliano RP, McCabe CH, Coussement P, et al. Combination reperfusion therapy with abciximab and reduced dose reteplase: Results from TIMI 14. Eur Heart J 2000;21:1944-53.
85. Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation 1997;95:846-54.
86. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. Lancet 2001;357:1905-14.
87. Ronner E, Van Kesteren HAM, Zijnen P, Altmann E, Molhoek PG, Van Der Wieken LR, et al. Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction: A phase II dose escalation, randomized, double-blind study. Eur Heart J 2000;21:1530-6.
88. Hillegas WB, Newman AR, Raco DL. Economic issues in glycoprotein IIb/IIIa receptor therapy. Am Heart J 1999;138(1 Pt 2):S24-S32.
89. Mark DB, Harrington RA, Lincoff AM, Califf RM, Nelson CL, Tsiatis AA, et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 2000;101:366-71.
90. McElwee NE, Johnson ER. Potential economic impact of glycoprotein IIb-IIIa inhibitors in improving outcomes of patients with acute ischemic coronary syndromes. Am J Cardiol 1997;80(4A):39B-43B.
91. Bell DM. Analysis of number needed to treat and cost of platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions and acute coronary syndromes. Pharmacotherapy 1999;19:1086-93.
92. Szucs TD, Meyer BJ, Kiowski W. Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting. An analysis based on the PRISM PLUS trial. Eur Heart J 1999;20:1253-60.
93. Schering-Plough Ltd. Eptifibatide in Treating Acute Coronary Syndromes in the United Kingdom. Submission to the National Institute for Clinical Excellence. Welwyn Garden City: Schering-Plough; April 2000.
94. Merck Sharp & Dohme Ltd. AGGRASTAT (Tirofiban) in the Treatment of Unstable Angina and Coronary Syndromes. Sponsor submission to the National Institute for Clinical Excellence. Hoddesdon: Merck Sharp & Dohme; April 2000.
95. National Institute for Clinical Excellence. Technical Guidance for Manufacturers and Sponsors Making a Submission to a Technology Appraisal. London: NICE; 2001.
96. Collinson J, Flather M, Fox K, Findlay I, Rodrigues E, Dooley P, et al. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK). Eur Heart J 2000;21:1450-7.
97. Dunn CJ, Foster RH. Abciximab: A pharmacoeconomic review of its use in percutaneous coronary revascularisation. Pharmacoeconomics 1999;16:711-41.
98. Mark DB, Talley JD, Topol EJ, Bowman L, Lam LC, Anderson KM, et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation 1996;94:629-35.
99. Van Hout BA, Simoons ML. Costs and effects of c7E3 in high risk PTCA patients. An indirect analysis for The Netherlands. Eur Heart J 1995;16:81-5.
100. Van Hout BA, Bowman L, Zelinger DJ, Simoons ML. Costs and effects in therapy for acute coronary syndromes: The case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. Eur Heart J 1998;19 Suppl D:D59-66.
101. Anderson KM, Bala MV, Weisman HF. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. An industry perspective on health economics studies. Am Heart J 1999;137:S129-32.
102. Sacristan JA, Navarro O, Huete T, Iniguez A. Cost-effectiveness of the monoclonal antibody c7E3 in high-risk coronary angioplasty in Spain. Br J Med Econ 1996;10:169-83.
103. Zed PJ, Frighetto L, Sunderji R, Marra CA. Cost-effectiveness analysis of abciximab: A Canadian hospital perspective. Ann Pharmacother 1998;32:536-42.
104. Aristides M, Gliksman M, Rajan N, Davey P. Effectiveness and cost effectiveness of single bolus treatment with abciximab (ReoPro) in preventing restenosis following percutaneous transluminal coronary angioplasty in high risk patients. Heart 1998;79:12-17.
105. Goklaney AK, Murphy JD, Hillegass WB. Abciximab therapy in percutaneous intervention: Economic issues in the United States. Am Heart J 1998;135:S90-7.
106. Lorenzoni R, Mazzotta G, Gensini GF, De Caterina R. Economic evaluation of abciximab in the pre-treatment of patients undergoing percutaneous transluminal coronary angioplasty in the context of the Italian health-care system. G Ital Cardiol 1999;29:269-76.
107. McGregor M, Brophy JM. Use of abciximab (c7E3 Fab, ReoPro) as an adjunct to balloon angioplasty. Can J Cardiol 1999;15:201-7.
108. Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1999;354:2019-24.
109. Weinbtraub WS, Culler S, Boccuzzi SJ, Cook JR, Kosinski AS, Cohen DJ, et al. Economic impact of GPIIB/IIIA blockade after high-risk angioplasty: Results from the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. J Am Coll Cardiol 1999;34:1061-6.
110. Hermiller J, Kereiakes DJ. Economic considerations in the use of the platelet GP IIb/IIIa inhibitor abciximab in percutaneous coronary intervention. Eur Heart Journal 1999;20 Suppl E:E43-8.
111. Reed SO, Mullins CD, Magder LS. Cost effectiveness of abciximab during routine medical practice. Pharmacoeconomics 2000;18:265-74.
112. Weintraub WS, Thompson TD, Culler S, Boccuzzi SJ, Becker ER, Kosinski S, et al. Targeting patients undergoing angioplasty for thrombus inhibition: A cost-effectiveness and decision support model. Circulation 2000;102:392-8.
113. Henderson RA, Brown R. The costs of routine eptifibatide use in acute coronary syndromes in Western Europe: An economic substudy of the PURSUIT trial. Eur Heart J Suppl 1999;1 (N):N35-41.
114. Kereiakes DJ. Costs and effects in therapy for acute coronary syndromes: The case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. Am J Cardiol 1998;81 (7A):49E-54E.
115. Zwart-Van Rijkom JE, Van Hout BA. Cost-efficacy in interventional cardiology; Results from the EPISTENT study. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial. Eur Heart J 2001;22:1476-84.
116. Eli Lilly & Co Ltd. ReoPro (Abciximab) in Unstable Angina and Acute Coronary Syndromes. Submission to the National Institute for Clinical Excellence on behalf of Eli Lilly & Co Ltd & Centocor BVÅ; 2000.
117. Zed PJ, Frighetto L, Sunderji R, Marra CA. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Ann Pharmacother 1998;32:536-42.
118. Mehta SR, Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 2000;21:2033-41.
119. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358:527-33.
120. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: A comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol 2000;35:1535-42.
121. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996;28:1328-428.
122. Higgins JP, Whitehead A, Turner RM, Omar RZ, Thompson SG. Meta-analysis of continuous outcome data from individual patients. Stat Med 2001;20:2219-41.
123. Newby LK, Ohman EM, Christenson RH, Moliterno DJ, Harrington RA, White HD, et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: The PARAGON-B troponin T substudy. Circulation 2001;103:2891-6.